VALEO PHARMA PROVIDING GUIDANCE OF RECORD REVENUES FOR THE SECOND QUARTER 2023
Q2-23 revenues to exceed $13.5 million
Q2-23 adjusted EBITDA loss to decrease below $2.0 million
Q2-23 operating expenses to remain in line with prior quarters
ENERZAIR® and ATECTURA® quarterly revenues grow 270% over prior year
MONTREAL, May 25, 2023 /CNW/ - Valeo Pharma Inc. (TSX: VPH) (OTCQB: VPHIF) (FSE: VP2) ("Valeo" or the "Company"), a Canadian pharmaceutical company, today provided a financial and commercial update ahead of its second quarter 2023 results.
Q2-23 Financial Update:
Based on currently available information, the Company is providing the following guidance updates for its second quarter 2023. The Company expects:
Revenues to exceed $13.5 million, a sixth consecutive quarter of revenue growth and a quarterly record
Adjusted EBITDA loss to drop below $2.0 million, a sixth consecutive quarter of adjusted EBITDA loss reduction
Operating expenses to remain in line with prior quarters
"We are displaying continued quarterly revenue growth and overall improvement in our financial performance. Our core products have grown significantly on a year-over-year basis and we see continuing gains ahead. We are especially pleased with the increased physician and patient adoption of our innovative asthma therapies which have long growth runways ahead of them", said Steve Saviuk, CEO. "Our business development efforts are focused on adding additional core products in the near term to leverage our operational and commercial platform and accelerate our timeline to profitability".
Q2-23 Commercial Update:
On the commercial front, the Company is pleased to report that:
ENERZAIR® and ATECTURA® total number of prescribing physicians (generalists and specialists) continued to grow and is now expected to exceed 2,000 at the end of April, 2023
ENERZAIR® and ATECTURA® quarterly revenues showed accelerating growth, increasing 270% over the corresponding period last year
ALLERJECT® promotional activities have officially launched in April 2023
XIIDRA®'s and SIMBRINZA® have delivered their best quarterly sales performance since Valeo launched commercial activities
REDESCA® revenues continued to grow on year-over-year basis and continues to lead the Low Molecular Weight Heparin biosimilar market in Canada with more than 50% market share
About Valeo Pharma
Valeo Pharma is a fast growing Canadian pharmaceutical company dedicated to the commercialization of innovative prescription products in Canada with a focus on Respiratory/Allergy, Ophthalmology and Hospital Specialty Products. Headquartered in Kirkland, Quebec Valeo Pharma has all the required capabilities and the full infrastructure to register and properly manage its growing product portfolio through all stages of commercialization. For more information, please visit www.valeopharma.com and follow us on LinkedIn and Twitter.
Forward Looking Statements
This press release contains forward-looking statements about Valeo's objectives, strategies and businesses that involve risks and uncertainties. These statements are "forward-looking" because they are based on our current expectations about the markets we operate in and on various estimates and assumptions. Actual events or results may differ materially from those anticipated in these forward-looking statements if known or unknown risks affect our business, or if our estimates or assumptions turn out to be inaccurate.
Prestigious medical schools continue to discriminate based on race and are committed to continue to find work arounds to the Supreme Court's ruling in Students for Fair Admissions v. Harvard and Students for Fair Admissions v. North Carolina are the...
Pretty Tasty Tea (Pretty Tasty), a beverage brand dedicated to innovating in the beauty space through its line of delicious and flavorful collagen teas, announced its ready-to-drink tea line is available now at Pop Up Grocer, the discovery...
AppYea Inc. , developer of an innovative wearable monitoring solution to monitor and treat sleep apnea and snoring, today announced the conversion of the majority of debt owed to its Chairman, Boris (Bary) Molchadsky, who converted approximately...
Radon Medical Imaging (Radon), a leading medical imaging equipment maintenance and repair services company, today announced it was selected as the Medical Imaging Asset Management firm for several Vandalia Health facilities. It is a multi-year,...
Today the American Pharmacists Association (APhA) announced the election of Magaly Rodriguez de Bittner, PharmD, FNAP, FAPhA, of Pasadena, MD, as 2025?2026 APhA president-elect. Rodrigeuz de Bittner will succeed Randy P. McDonough, BS, PharmD, MS,...
In a world where medical breakthroughs and technological advancements intertwine, the Dr. Samuel Clanton Scholarship for Medical Students emerges as a beacon of opportunity for aspiring healthcare leaders. Established to honor the illustrious legacy...